Celmatix Announces Achievement of Key Preclinical Milestones in Premature Menopause Prevention Drug Program
The program, which was a product of Celmatixs decade-long focus on identifying novel biomarkers and drug targets for womens health, has a planned first clinical indication in the prevention of premature menopause in women undergoing chemotherapy.
- The program, which was a product of Celmatixs decade-long focus on identifying novel biomarkers and drug targets for womens health, has a planned first clinical indication in the prevention of premature menopause in women undergoing chemotherapy.
- Loss of ovarian function and menopause are accelerated by approximately 1.5 years for each month a woman receives chemotherapy treatment.
- A century ago, the average life expectancy for women globally was under 50, so most women did not live long enough to experience menopause.
- The milestone was triggered by Evotec and Bayer AG advancing a drug program, centered around a novel Celmatix-identified drug target, into hit-identification.